Subtopic Deep Dive
Drug-Eluting Stents
Research Guide
What is Drug-Eluting Stents?
Drug-eluting stents (DES) are coronary stents coated with polymers that release antiproliferative drugs like sirolimus or paclitaxel to inhibit neointimal hyperplasia and prevent restenosis after percutaneous coronary intervention (PCI).
First-generation DES, including sirolimus- and paclitaxel-eluting stents, reduced target lesion revascularization rates compared to bare-metal stents (Stone et al., 2007; 1620 citations). Second-generation devices improved long-term safety by addressing late stent thrombosis risks observed in Swedish registry data (Lagerqvist et al., 2007; 1186 citations). Guidelines from ESC/EACTS (Windecker et al., 2014; 4287 citations) and ACCF/AHA/SCAI (Levine et al., 2011; 3289 citations) endorse DES as standard for most PCI cases.
Why It Matters
DES transformed PCI by slashing restenosis rates from over 30% with bare-metal stents to under 10%, enabling safer treatment of complex lesions in stable and acute coronary syndromes (Stone et al., 2007). Long-term data revealed higher late thrombosis risks, prompting polymer and drug refinements that cut death and MI composites in real-world use (Lagerqvist et al., 2007). Guidelines integrate DES into revascularization strategies, reducing urgent revascularizations in FFR-guided PCI (De Bruyne et al., 2012; 2666 citations) and standardizing MI definitions for outcome tracking (Thygesen et al., 2012; 2049 citations).
Key Research Challenges
Late Stent Thrombosis Risk
First-generation DES showed increased stent thrombosis after 1 year versus bare-metal stents, raising death rates in long-term follow-up (Stone et al., 2007; Lagerqvist et al., 2007). Balancing drug release kinetics with endothelialization remains critical. Guidelines highlight dual antiplatelet therapy duration as a mitigation factor (Windecker et al., 2014).
Polymer Hypersensitivity
Non-erodible polymers in early DES triggered inflammation, contributing to restenosis and thrombosis in subset analyses (Lagerqvist et al., 2007). Biodegradable alternatives aim to improve vessel healing. Comparative trials underscore coating durability needs (Stone et al., 2007).
Patient Subgroup Variability
DES benefits vary in diabetes, small vessels, and off-label use, with higher adverse events in registries (Lagerqvist et al., 2007). Guidelines stratify recommendations by lesion complexity and ACS presentation (Levine et al., 2011; Windecker et al., 2014). Personalized risk models are needed for diverse populations.
Essential Papers
2014 ESC/EACTS Guidelines on myocardial revascularization
Stephan Windecker, Philippe Kolh, Fernándo Alfonso et al. · 2014 · European Heart Journal · 4.3K citations
peer reviewed
2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention
Glenn N. Levine, Eric Bates, James C. Blankenship et al. · 2011 · Circulation · 3.3K citations
ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: The Task Force for the management of acute coronary syndromes (ACS) in patients presenting without persistent ST-segment elevation of the European Society of Cardiology (ESC)
C Hamm, Jean‐Pierre Bassand, Stefan Agewall et al. · 2011 · European Heart Journal · 3.1K citations
peer reviewed
Fractional Flow Reserve–Guided PCI versus Medical Therapy in Stable Coronary Disease
Bernard De Bruyne, Nico H.J. Pijls, Bindu Kalesan et al. · 2012 · New England Journal of Medicine · 2.7K citations
In patients with stable coronary artery disease and functionally significant stenoses, FFR-guided PCI plus the best available medical therapy, as compared with the best available medical therapy al...
Third universal definition of myocardial infarction
the Writing Group on behalf of the Joint ESC/ACCF/AHA/WHF Task Force for the Universal Definition of Myocardial Infarction, Kristian Thygesen, Joseph S. Alpert et al. · 2012 · Nature Reviews Cardiology · 2.0K citations
2009 Focused Updates: ACC/AHA Guidelines for the Management of Patients With ST-Elevation Myocardial Infarction (Updating the 2004 Guideline and 2007 Focused Update) and ACC/AHA/SCAI Guidelines on Percutaneous Coronary Intervention (Updating the 2005 Guideline and 2007 Focused Update)
Frederick G. Kushner, Mary M. Hand, Sidney C. Smith et al. · 2009 · Circulation · 1.7K citations
Safety and Efficacy of Sirolimus- and Paclitaxel-Eluting Coronary Stents
Gregg W. Stone, Jeffrey W. Moses, Stephen G. Ellis et al. · 2007 · New England Journal of Medicine · 1.6K citations
Stent thrombosis after 1 year was more common with both sirolimus-eluting stents and paclitaxel-eluting stents than with bare-metal stents. Both drug-eluting stents were associated with a marked re...
Reading Guide
Foundational Papers
Start with Stone et al. (2007) for RCT evidence on sirolimus/paclitaxel efficacy and thrombosis signals; follow with Lagerqvist et al. (2007) for registry long-term outcomes; then Windecker et al. (2014) and Levine et al. (2011) for guideline consensus.
Recent Advances
Prioritize De Bruyne et al. (2012) for FFR-guided DES use and Thygesen et al. (2012) for MI definitions in trials; Hamm et al. (2011) covers ACS applications.
Core Methods
Primary endpoints include target lesion failure (revascularization, MI, death); imaging assesses neointimal hyperplasia; pharmacokinetics model drug elution (Stone et al., 2007).
How PapersFlow Helps You Research Drug-Eluting Stents
Discover & Search
PapersFlow's Research Agent uses searchPapers and citationGraph to map DES evolution from Stone et al. (2007) to Windecker et al. (2014), revealing 4287 citations linking guidelines to trials. exaSearch uncovers registry data like Lagerqvist et al. (2007), while findSimilarPapers expands to FFR-guided PCI impacts (De Bruyne et al., 2012).
Analyze & Verify
Analysis Agent applies readPaperContent to extract thrombosis rates from Stone et al. (2007), then verifyResponse with CoVe checks claims against Levine et al. (2011) guidelines. runPythonAnalysis computes survival curves from Lagerqvist et al. (2007) data using pandas for HR estimates, with GRADE grading assigning high evidence to RCTs versus moderate for registries.
Synthesize & Write
Synthesis Agent detects gaps in long-term safety between first- and second-generation DES, flagging contradictions in thrombosis data. Writing Agent uses latexEditText and latexSyncCitations to draft guideline-compliant reviews citing Windecker et al. (2014), with latexCompile generating figures and exportMermaid for risk timelines.
Use Cases
"Compare restenosis rates in sirolimus vs paclitaxel stents from RCTs"
Research Agent → searchPapers('sirolimus paclitaxel restenosis RCT') → Analysis Agent → runPythonAnalysis (extract rates from Stone et al. 2007, compute RR with SciPy) → outputs forest plot CSV and GRADE-scored meta-summary.
"Draft LaTeX review on DES guidelines evolution"
Synthesis Agent → gap detection (Windecker 2014 vs Levine 2011) → Writing Agent → latexEditText (structure sections) → latexSyncCitations (10 papers) → latexCompile → outputs polished PDF with auto-generated tables.
"Find simulation code for drug release kinetics in stents"
Research Agent → paperExtractUrls (DES polymer kinetics papers) → Code Discovery → paperFindGithubRepo → githubRepoInspect → outputs validated Python repo for Fickian diffusion models with NumPy runPythonAnalysis demo.
Automated Workflows
Deep Research workflow conducts systematic review of 50+ DES papers, chaining citationGraph from Stone et al. (2007) to generate structured report on thrombosis risks with GRADE scores. DeepScan's 7-step analysis verifies long-term outcomes in Lagerqvist et al. (2007) via CoVe checkpoints and Python meta-analysis. Theorizer builds hypotheses on polymer impacts from guideline contradictions (Windecker et al., 2014).
Frequently Asked Questions
What defines drug-eluting stents?
DES are stents releasing antiproliferative agents like sirolimus or paclitaxel via polymer coatings to prevent restenosis (Stone et al., 2007).
What methods characterize DES performance?
Trials measure target lesion revascularization, stent thrombosis, and death; registries track real-world outcomes (Stone et al., 2007; Lagerqvist et al., 2007).
What are key papers on DES?
Stone et al. (2007; 1620 citations) proves efficacy/safety; Lagerqvist et al. (2007; 1186 citations) shows long-term risks; Windecker et al. (2014; 4287 citations) provides guidelines.
What open problems exist in DES research?
Optimizing drug release for endothelialization, reducing late thrombosis in subgroups, and developing fully bioresorbable platforms (Lagerqvist et al., 2007; Windecker et al., 2014).
Research Coronary Interventions and Diagnostics with AI
PapersFlow provides specialized AI tools for your field researchers. Here are the most relevant for this topic:
AI Literature Review
Automate paper discovery and synthesis across 474M+ papers
Deep Research Reports
Multi-source evidence synthesis with counter-evidence
Paper Summarizer
Get structured summaries of any paper in seconds
AI Academic Writing
Write research papers with AI assistance and LaTeX support
Start Researching Drug-Eluting Stents with AI
Search 474M+ papers, run AI-powered literature reviews, and write with integrated citations — all in one workspace.